| Literature DB >> 32754627 |
Satoshi Kutsuna1, Tadaki Suzuki2, Kayoko Hayakawa1, Shinya Tsuzuki3, Yusuke Asai3, Tetsuya Suzuki1, Satoshi Ide1, Keiji Nakamura1, Yuki Moriyama1, Noriko Kinoshita1, Naoto Hosokawa4, Ryosuke Osawa4, Ryosuke Yamamuro4, Yutaro Akiyama1, Yusuke Miyazato1, Hidetoshi Nomoto1, Takato Nakamoto1, Masayuki Ota1, Sho Saito1, Masahiro Ishikane1, Shinichiro Morioka1, Kei Yamamoto1, Mugen Ujiie1, Mari Terada1, Fukumi Nakamura-Uchiyama5, Toshinori Sahara5, Masahiro Sano6, Akifumi Imamura7, Noritaka Sekiya8, Kazuaki Fukushima7, Akihiko Kawana9, Yuji Fujikura9, Tomoya Sano9, Ryohei Suematsu9, Naoya Sakamoto10, Kaoru Nagata11, Tomoyuki Kato11, Harutaka Katano2, Takaji Wakita2, Haruhito Sugiyama12, Norihiro Kokudo12, Norio Ohmagari1.
Abstract
BACKGROUND: Severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) was found to be the causative microorganism of coronavirus disease 2019 (COVID-19), which started to spread in Wuhan, China. This study was to evaluate the effectiveness of questionnaire, symptoms-based screening, and polymerase chain reaction (PCR) screening of returnees from COVID-19-endemic areas on a chartered flight, to examine the proportion of infected persons and the proportion of asymptomatic persons among infected persons who returned from Wuhan.Entities:
Keywords: COVID-19; SARS-CoV-2; Wuhan; lockdown; returnees
Year: 2020 PMID: 32754627 PMCID: PMC7337761 DOI: 10.1093/ofid/ofaa243
Source DB: PubMed Journal: Open Forum Infect Dis ISSN: 2328-8957 Impact factor: 3.835
Figure 1.Flow of 566 people returning from Wuhan on a charter flight. Cases surrounded by red line represent polymerase chain reaction positives. Abbreviation: PCR, polymerase chain reaction.
Characteristics of Evacuated People From Wuhan to Japan, January 2020
| PCR Positive | PCR Negative |
| |
|---|---|---|---|
| No. | 11 | 553 | |
| Median age (range), y | 49 (30–65) | 42 (1–70) | .042 |
| Male, No. (%) | 8 (72.7) | 511 (92.4) | .050 |
| Arrival date, No. (%) | |||
| Jan 29 | 5 (45.5) | 199 (36.0) | |
| Jan 30 | 3 (27.3) | 207 (37.4) | |
| Jan 31 | 3 (27.3) | 147 (26.6) | |
| Contact history, No. (%) | |||
| Contact with person(s) with respiratory symptoms | 1 (9.1) | 73 (13.2) | 1.0 |
| Contact with COVID-19 patients | 1 (9.1) | 24 (4.3) | .396 |
| Fever (quartile range), ºC | 36.9 (36.7–37.3) | 36.7 (36.5–36.9) | <.043 |
| Respiratory symptoms, No. (%) | 3 (27.3) | 60 (10.8) | .114 |
| Cough | 2 (18.2) | 37 (6.7) | .173 |
| Runny nose | 1 (9.1) | 26 (4.7) | .420 |
| Sore throat | 0 (0) | 15 (2.7) | 1.0 |
| Sputum | 0 (0) | 2 (.4) | 1.0 |
| Headache, No. (%) | 0 (0) | 5 (.9) | 1.0 |
| Fatigue, No. (%) | 0 (0) | 14 (2.5) | 1.0 |
| Other, No. (%) | 0 (0) | 11 (2.0) | 1.0 |
| Any drug use, No. (%) | 2 (18.2) | 16 (2.9) | .045 |
Abbreviations: COVID-19, coronavirus disease; PCR, polymerase chain reaction.
aFisher exact test for categorical variables and Mann-Whitney U test for quantitative variables.
Detail Clinical Information of PCR Positive 11 Patients
| Age | Gender | Arrival Date | Onset | First PCRScreening on Arrival | Additional PCRBased on Clinical Symptoms | Second PCRScreening at Day 12 | Comorbidities | Exposure With Confirmed Cases in Wuhan | Exposure to ILI | URI Symptoms at First Consultation | BT at First Consultation, ℃ | Complication | Outcome | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Symptomatic | S1 | 50s | M | 29 Jan | 29 Jan | Positive (29 Jan) | NA | NA | None | No | No | Runny nose,sore throat | 37.1 | Viral pneumonia | Discharged on 22 Feb |
| S2 | 40s | M | 29 Jan | 26 Jan | Negative (29 Jan) | Positive (31 Jan) | NA | None | No | No | Cough,headache, conjunctivitis | 37.6 | Viral pneumonia | Discharged on 13 Feb | |
| S3 | 50s | M | 29 Jan | 6 Feb | Negative (29 Jan) | Positive (7 Feb) | NA | None | No | No | Cough, shortness of breath | 38.5 | Viral pneumonitis | Discharged on 14 Feb | |
| S4 | 50s | F | 30 Jan | 30 Jan | Negative (30 Jan) | Positive (3 Feb) | NA | None | Yes (19 Jan) | No | Diarrheacoughsore throat | 37.5 | Viral pneumonia | Discharged on 14 Feb | |
| S5 | 40s | M | 31 Jan | 31 Jan | Positive (31 Jan) | NA | NA | None | No | No | Cough | 38.2 | Viral pneumonitis | Discharged on 22 Feb | |
| Asymptomatic | A1 | 40s | M | 29 Jan | 31 Jan | Positive (29 Jan) | NA | NA | None | No | No | None | 36.3 | None | Discharged on 1 Mar |
| A2 | 50s | F | 29 Jan | None | Positive (29 Jan) | NA | NA | None | No | No | None | 36.4 | None | Discharged on 13 Feb | |
| A3 | 30s | M | 30 Jan | None | Positive (30 Jan) | NA | NA | None | No | No | None | 37.1 | None | Discharged on 14 Feb | |
| A4 | 50s | M | 30 Jan | 31 Jan | Positive (30 Jan) | NA | NA | None | No | No | None | 36.9 | None | Discharged on 26 Feb | |
| A5 | 30s | M | 31 Jan | None | Positive (31 Jan) | NA | NA | Mild liver disease | No | No | None | 36.6 | None | Discharged on 19 Feb | |
| A6 | 60s | F | 31 Jan | None | Negative (31 Jan) | NA | Positive (13 Feb) | None | No | No | None | 36.6 | None | Discharged on 21 Feb |
Abbreviations: BT, body temperature; Feb, February; F, female; ILI, influenza-like illness; Jan, January; M, male; Mar, March; PCR, polymerase chain reaction; URI, upper respiratory infection.
Figure 2.Clinical symptoms and virus copy numbers in pharyngeal swab samples of 5 patients with severe acute respiratory syndrome–related coronavirus 2 (SARS-CoV-2) infection. Copy numbers in 1 μL of the swab samples were measured with real-time reverse transcription polymerase chain reaction (RT-PCR) targeting the SARS-CoV2 N1 gene. aPositive results of A1, 4, 5, and 6 patients were obtained with real-time RT-PCR, but not quantified.